Organic-Vaccines, a company specializing in using biotechnology to utilize a patient’s own cells for treatments, recently applied to the World Health Organization (WHO) for compassionate use of the company’s MERS-CoV (Middle-East Respiratory Syndrome Coronavirus) vaccine.
The first confirmed cases of MERS-CoV occurred in Saudi Arabia in 2012. Since then, 804 cases have been reported in the country with 43 percent of patients dying as of Thursday. Worldwide, WHO has reported 887 cases of MERS-CoV as of Oct. 16.
Organic-Vaccines is preparing its vaccine in order to respond rapidly to future MERS-CoV cases. Early preparation is key to protecting health professionals, first responders and citizens, as well as preventing worldwide pandemics.
via Organic-Vaccines seeks “compassionate use” of its MERS-CoV vaccine | Vaccine News Daily.
Ned Hamson's Second Line View of the News 